Adrenomedullin in heart failure: potential therapeutic implications
| Autor: | Miriam T. Rademaker, A.M. Richards, Christopher J. Charles, M G Nicholls |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Cardiac output Aldosterone business.industry Hemodynamics medicine.disease Adrenomedullin chemistry.chemical_compound Blood pressure chemistry Internal medicine Heart failure Cardiology Molecular Medicine Medicine Myocardial infarction Cardiology and Cardiovascular Medicine business Neprilysin |
| Zdroj: | Future Cardiology. 1:235-243 |
| ISSN: | 1744-8298 1479-6678 |
| DOI: | 10.1517/14796678.1.2.235 |
| Popis: | Adrenomedullin (AM) may play a role in the pathophysiology of heart failure. Plasma levels of AM are raised in cardiovascular disease in proportion to severity of cardiac dysfunction, and plasma AM levels measured in acute myocardial infarction and heart failure are a useful prognostic indicator of outcome. AM administration in both experimental and human heart failure induces a beneficial spectrum of biological action including reduced arterial and atrial pressures, improved cardiac output, inhibition of plasma aldosterone and preservation or augmentation of urinary sodium excretion. Combining AM administration with either angiotensin-converting enzyme inhibition or neutral endopeptidase inhibition results in augmentation of the hemodynamic and renal effects of the individual treatments. Manipulating the AM system may prove beneficial as an adjunctive therapeutic strategy in cardiac disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|